Do analysts rate CABR or XRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caring Brands 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, CABR or XRTX?

Caring Brands is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Caring Brands N/A N/A -$6.28M -$0.74 N/A XORTX Therapeutics N/A N/A -$2.66M -$2.73 N/A

Is CABR or XRTX more profitable?

XORTX Therapeutics' return on equity of -137.85% beat Caring Brands' return on equity. Company Net Margins Return on Equity Return on Assets Caring Brands N/A -1,153.12% -322.63% XORTX Therapeutics N/A -137.85% -108.16%

Do analysts recommend INTS or XRTX?

Intensity Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 64.71%. Given Intensity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Intensity Therapeutics is more favorable than XORTX Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intensity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, INTS or XRTX?

Intensity Therapeutics is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Intensity Therapeutics N/A N/A -$11.61M -$3.57 N/A XORTX Therapeutics N/A N/A -$2.66M -$2.73 N/A

Is INTS or XRTX more profitable?

Intensity Therapeutics' return on equity of -116.61% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Intensity Therapeutics N/A -116.61% -94.01% XORTX Therapeutics N/A -137.85% -108.16%

Do analysts prefer DARE or XRTX?

Dare Bioscience currently has a consensus price target of $10.00, suggesting a potential upside of 1,260.54%. Given Dare Bioscience's stronger consensus rating and higher possible upside, research analysts plainly believe Dare Bioscience is more favorable than XORTX Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to DARE or XRTX?

In the previous week, Dare Bioscience had 2 more articles in the media than XORTX Therapeutics. MarketBeat recorded 5 mentions for Dare Bioscience and 3 mentions for XORTX Therapeutics. XORTX Therapeutics' average media sentiment score of 0.63 beat Dare Bioscience's score of 0.37 indicating that XORTX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral XORTX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ELOX or XRTX?

Eloxx Pharmaceuticals presently has a consensus price target of $41.50, suggesting a potential upside of 175.38%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Eloxx Pharmaceuticals is more favorable than XORTX Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eloxx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ELOX or XRTX more profitable?

Eloxx Pharmaceuticals' return on equity of 0.00% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eloxx Pharmaceuticals N/A N/A N/A XORTX Therapeutics N/A -137.85% -108.16%

Does the media favor ELOX or XRTX?

In the previous week, Eloxx Pharmaceuticals and Eloxx Pharmaceuticals both had 3 articles in the media. XORTX Therapeutics' average media sentiment score of 0.63 beat Eloxx Pharmaceuticals' score of 0.62 indicating that XORTX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XORTX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend FNCH or XRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, FNCH or XRTX?

XORTX Therapeutics is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A XORTX Therapeutics N/A N/A -$2.66M -$2.73 N/A

Is FNCH or XRTX more profitable?

Finch Therapeutics Group's return on equity of -69.14% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% XORTX Therapeutics N/A -137.85% -108.16%

XORTX Therapeutics (XRTX) Competitors

$2.34 -0.10 (-4.10%)

As of 08/28/2026 03:59 PM Eastern

Compare

XRTX vs. CABR, INTS, DARE, ELOX, and FNCH

Should you buy XORTX Therapeutics stock or one of its competitors? XORTX Therapeutics's main competitors and comparable companies include Caring Brands (CABR), Intensity Therapeutics (INTS), Dare Bioscience (DARE), Eloxx Pharmaceuticals (ELOX), and Finch Therapeutics Group (FNCH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does XORTX Therapeutics compare to Caring Brands?

Caring Brands (NASDAQ:CABR) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

0.2% of XORTX Therapeutics shares are held by institutional investors. 14.6% of Caring Brands shares are held by insiders. Comparatively, 6.9% of XORTX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Caring Brands is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caring Brands	N/A	N/A	-$6.28M	-$0.74	N/A
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.73	N/A

XORTX Therapeutics' return on equity of -137.85% beat Caring Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caring Brands	N/A	-1,153.12%	-322.63%
XORTX Therapeutics	N/A	-137.85%	-108.16%

In the previous week, XORTX Therapeutics had 1 more articles in the media than Caring Brands. MarketBeat recorded 3 mentions for XORTX Therapeutics and 2 mentions for Caring Brands. XORTX Therapeutics' average media sentiment score of 0.63 beat Caring Brands' score of 0.45 indicating that XORTX Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Caring Brands	Neutral
XORTX Therapeutics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caring Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

XORTX Therapeutics beats Caring Brands on 6 of the 8 factors compared between the two stocks.

How does XORTX Therapeutics compare to Intensity Therapeutics?

Intensity Therapeutics (NASDAQ:INTS) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Intensity Therapeutics has a beta of 2.76, indicating that its share price is 176% more volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

3.7% of Intensity Therapeutics shares are held by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are held by institutional investors. 7.6% of Intensity Therapeutics shares are held by company insiders. Comparatively, 6.9% of XORTX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Intensity Therapeutics is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$3.57	N/A
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.73	N/A

Intensity Therapeutics' return on equity of -116.61% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-116.61%	-94.01%
XORTX Therapeutics	N/A	-137.85%	-108.16%

Intensity Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 64.71%. Given Intensity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Intensity Therapeutics is more favorable than XORTX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, XORTX Therapeutics had 2 more articles in the media than Intensity Therapeutics. MarketBeat recorded 3 mentions for XORTX Therapeutics and 1 mentions for Intensity Therapeutics. Intensity Therapeutics' average media sentiment score of 1.87 beat XORTX Therapeutics' score of 0.63 indicating that Intensity Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Intensity Therapeutics	Very Positive
XORTX Therapeutics	Positive

Summary

Intensity Therapeutics beats XORTX Therapeutics on 10 of the 13 factors compared between the two stocks.

How does XORTX Therapeutics compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Dare Bioscience currently has a consensus price target of $10.00, suggesting a potential upside of 1,260.54%. Given Dare Bioscience's stronger consensus rating and higher possible upside, research analysts plainly believe Dare Bioscience is more favorable than XORTX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dare Bioscience has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by company insiders. Comparatively, 6.9% of XORTX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

XORTX Therapeutics has lower revenue, but higher earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	14.04	-$13.40M	-$0.70	N/A
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.73	N/A

XORTX Therapeutics has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. XORTX Therapeutics' return on equity of -137.85% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-748.30%	-38.75%
XORTX Therapeutics	N/A	-137.85%	-108.16%

In the previous week, Dare Bioscience had 2 more articles in the media than XORTX Therapeutics. MarketBeat recorded 5 mentions for Dare Bioscience and 3 mentions for XORTX Therapeutics. XORTX Therapeutics' average media sentiment score of 0.63 beat Dare Bioscience's score of 0.37 indicating that XORTX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
XORTX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Dare Bioscience beats XORTX Therapeutics on 9 of the 15 factors compared between the two stocks.

How does XORTX Therapeutics compare to Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Eloxx Pharmaceuticals presently has a consensus price target of $41.50, suggesting a potential upside of 175.38%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Eloxx Pharmaceuticals is more favorable than XORTX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Eloxx Pharmaceuticals has a beta of -1863.11, meaning that its share price is 186,411% less volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of XORTX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Eloxx Pharmaceuticals' return on equity of 0.00% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
XORTX Therapeutics	N/A	-137.85%	-108.16%

In the previous week, Eloxx Pharmaceuticals and Eloxx Pharmaceuticals both had 3 articles in the media. XORTX Therapeutics' average media sentiment score of 0.63 beat Eloxx Pharmaceuticals' score of 0.62 indicating that XORTX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XORTX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

XORTX Therapeutics has lower revenue, but higher earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36M	9.57	-$5.99M	-$1.54	N/A
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.73	N/A

Summary

Eloxx Pharmaceuticals beats XORTX Therapeutics on 10 of the 13 factors compared between the two stocks.

How does XORTX Therapeutics compare to Finch Therapeutics Group?

Finch Therapeutics Group (NASDAQ:FNCH) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

In the previous week, XORTX Therapeutics had 3 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 3 mentions for XORTX Therapeutics and 0 mentions for Finch Therapeutics Group. XORTX Therapeutics' average media sentiment score of 0.63 beat Finch Therapeutics Group's score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
XORTX Therapeutics	Positive

21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 6.9% of XORTX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Finch Therapeutics Group's return on equity of -69.14% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
XORTX Therapeutics	N/A	-137.85%	-108.16%

XORTX Therapeutics is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.73	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Finch Therapeutics Group has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

Summary

Finch Therapeutics Group beats XORTX Therapeutics on 6 of the 11 factors compared between the two stocks.

Get XORTX Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XRTX vs. The Competition

Export

Metric	XORTX Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.25M	$12.17B	$7.21B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-0.86	651.65	212.62	21.91
Price / Sales	N/A	755.84	625.86	92.63
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	1.56	10.49	11.08	6.36
Net Income	-$2.66M	$2.83B	$3.48B	$349.79M
7 Day Performance	14.71%	0.39%	0.13%	-0.80%
1 Month Performance	15.84%	5.34%	7.08%	4.13%
1 Year Performance	-41.82%	6.05%	24.67%	15.17%

XORTX Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XRTX XORTX Therapeutics	1.1513 of 5 stars	$2.34 -4.1%	N/A	-43.6%	$4.25M	N/A	N/A	N/A	News Coverage Gap Down High Trading Volume
CABR Caring Brands	0.326 of 5 stars	$1.33 -4.3%	N/A	N/A	$14.41M	N/A	N/A	4	Short Interest Increase Gap Up
INTS Intensity Therapeutics	3.5153 of 5 stars	$4.88 +16.2%	$7.00 +43.4%	-39.3%	$13.71M	N/A	N/A	2,021	Positive News High Trading Volume
DARE Dare Bioscience	2.6159 of 5 stars	$0.81 -1.8%	$10.00 +1,135.8%	-63.6%	$12.60M	$1.03M	N/A	30	Analyst Upgrade Gap Up
ELOX Eloxx Pharmaceuticals	4.2761 of 5 stars	$18.04 -0.7%	$41.50 +130.0%	N/A	$12.50M	$6.36M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XRTX) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XORTX Therapeutics (XRTX) Competitors

XRTX vs. CABR, INTS, DARE, ELOX, and FNCH

How does XORTX Therapeutics compare to Caring Brands?

Summary

How does XORTX Therapeutics compare to Intensity Therapeutics?

Summary

How does XORTX Therapeutics compare to Dare Bioscience?

Summary

How does XORTX Therapeutics compare to Eloxx Pharmaceuticals?

Summary

How does XORTX Therapeutics compare to Finch Therapeutics Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XRTX vs. The Competition

XORTX Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XORTX Therapeutics (XRTX) Competitors

XRTX vs. CABR, INTS, DARE, ELOX, and FNCH

How does XORTX Therapeutics compare to Caring Brands?

Do insiders and institutionals hold more shares of CABR or XRTX?

Which has higher earnings & valuation, CABR or XRTX?

Is CABR or XRTX more profitable?

Does the media favor CABR or XRTX?

Do analysts rate CABR or XRTX?

Summary

How does XORTX Therapeutics compare to Intensity Therapeutics?

Which has more risk & volatility, INTS or XRTX?

Do institutionals & insiders hold more shares of INTS or XRTX?

Which has preferable valuation and earnings, INTS or XRTX?

Is INTS or XRTX more profitable?

Do analysts recommend INTS or XRTX?

Does the media favor INTS or XRTX?

Summary

How does XORTX Therapeutics compare to Dare Bioscience?

Do analysts prefer DARE or XRTX?

Which has more risk & volatility, DARE or XRTX?

Do insiders & institutionals hold more shares of DARE or XRTX?

Which has higher earnings and valuation, DARE or XRTX?

Is DARE or XRTX more profitable?

Does the media refer more to DARE or XRTX?

Summary

How does XORTX Therapeutics compare to Eloxx Pharmaceuticals?

Do analysts prefer ELOX or XRTX?

Which has more risk & volatility, ELOX or XRTX?

Do insiders & institutionals believe in ELOX or XRTX?

Is ELOX or XRTX more profitable?

Does the media favor ELOX or XRTX?

Which has preferable valuation and earnings, ELOX or XRTX?

Summary

How does XORTX Therapeutics compare to Finch Therapeutics Group?

Does the media prefer FNCH or XRTX?

Do institutionals and insiders have more ownership in FNCH or XRTX?

Is FNCH or XRTX more profitable?

Which has preferable valuation and earnings, FNCH or XRTX?

Do analysts recommend FNCH or XRTX?

Which has more volatility and risk, FNCH or XRTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XRTX vs. The Competition

XORTX Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools